2023
Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency
Silberzweig J, Kliger A, White D, Stark S, Kumar V. Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency. Clinical Journal Of The American Society Of Nephrology 2023, 19: 263-265. PMID: 37642955, PMCID: PMC10861095, DOI: 10.2215/cjn.0000000000000303.Peer-Reviewed Original Research54 COVID-19 and Dialysis Patients
Silberzweig J, Kliger A. 54 COVID-19 and Dialysis Patients. 2023, 491-496. DOI: 10.1016/b978-0-323-79135-9.00054-9.ChaptersDialysis therapyIntermittent renal replacement therapyCOVID-19Continuous dialysis therapyAcute kidney injuryChronic kidney diseaseRenal replacement therapyAcute peritoneal dialysisAssociated risk factorsHome dialysis therapiesHigh rateDepartment of HealthKidney injuryDiabetes mellitusDialysis patientsFacility patientsPeritoneal dialysisKidney diseaseReplacement therapyDialysis programRisk factorsSevere diseaseMedical conditionsSubstantial burdenPatients
2022
Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle KR, Wong L, St. Peter W, Roberts G, Rangaswami J, Mottl A, Kliger A, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC, Argyropoulos C, Quaggin SE. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1092-1103. PMID: 35649722, PMCID: PMC9269635, DOI: 10.2215/cjn.02980322.Commentaries, Editorials and LettersConceptsDiabetic kidney diseaseKidney disease careKidney diseaseHealth care systemDisease careKidney failureGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsAngiotensin-converting enzyme inhibitorBreakthrough therapiesMajor public health challengeHealth care system supportCare systemAngiotensin receptor blockersCotransporter 2 inhibitorsHalf of patientsPocket drug costsIndividual health care systemsPublic health challengeHealth care professionalsValue-based careEligible patientsMineralocorticoid antagonistsCardiovascular events
2021
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius FC, Cherney D, Gee PO, Harris RC, Kliger A, Tuttle KR, Quaggin SE. Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2021, 16: 1590-1600. PMID: 34103350, PMCID: PMC8499007, DOI: 10.2215/cjn.18641120.Commentaries, Editorials and LettersConceptsRenin-angiotensin system inhibitorsDiabetic kidney diseaseIrbesartan Diabetic Nephropathy TrialCare of patientsKidney diseaseSystem inhibitorsNew therapiesAngiotensin II Antagonist Losartan (RENAAL) trialAngiotensin II type 1 receptor blockerDiabetic kidney disease progressionType 1 receptor blockerCardiovascular protective therapiesReduction of EndpointsKidney disease progressionKidney protective effectsRenin-angiotensin systemDiabetic Nephropathy TrialRisk of deathHigh residual riskHealth care providersPowerful new therapiesNephropathy TrialReceptor blockersDevastating complicationAntihypertensive agents
2000
Chronic renal insufficiency: Current understandings and their implications
Bolton W, Kliger A. Chronic renal insufficiency: Current understandings and their implications. American Journal Of Kidney Diseases 2000, 36: s4-s12. PMID: 11118153, DOI: 10.1053/ajkd.2000.19926.Commentaries, Editorials and LettersConceptsChronic renal insufficiencyHealthy People 2010Kidney diseaseComorbid conditionsRenal replacement therapyChronic kidney diseaseCare of patientsClear diagnostic criteriaPopulation-based surveyAvailable epidemiologic dataHealth care resourcesPractical screening testHealth care systemExpeditious referralRenal dysfunctionRenal insufficiencyUremic complicationsCreatinine levelsKidney failureReplacement therapyAppropriate referralBlack raceOptimal careSpecialty careMale gender